<DOC>
	<DOC>NCT01271998</DOC>
	<brief_summary>The primary purpose of this study is to determine the steady-state plasma pharmacokinetics (PK) and properties of TR-700 into the pulmonary epithelial lining fluid (ELF) and alveolar macrophages (AM) of healthy volunteers.</brief_summary>
	<brief_title>Pulmonary Disposition of TR-700 Following Once-Daily Oral 200 mg</brief_title>
	<detailed_description>No applicable.</detailed_description>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Torezolid phosphate</mesh_term>
	<criteria>Healthy males and females, between 18 and 55 years of age, inclusive Females must be nonpregnant, nonlactating, and either postmenopausal or surgically sterile or practicing an effective method of birth control Males must be surgically sterile, abstinent, or practicing an effective method of birth control BMI between 20 and 34.9 kg/m2, inclusive Allergy to lidocaine, midazolam, or other anesthetics/sedatives of similar classes Physiciandiagnosed migraine headaches within 3 years Previous enrollment in a TR701 or TR701 FA trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2016</verification_date>
	<keyword>antibiotic</keyword>
	<keyword>healthy subjects</keyword>
	<keyword>pharmacokinetics</keyword>
</DOC>